Tysabri and PML: Statute of Limitations for Claims in Michigan

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Targeted Risk Awareness

The legacy of general health and science information has long provided a foundation for public understanding of medical risks and therapeutic benefits. Within this broad context, the dissemination of knowledge about pharmaceutical interventions and their potential adverse effects has been a critical function. As the domain of mass production expands, the focus necessarily shifts from population-level health guidance to the specific, real-world implications of widespread drug distribution. This transition is particularly salient when considering the lifecycle of a biologic therapy such as Tysabri, which was developed and manufactured on a large scale for the treatment of certain chronic conditions. The very scale of production and distribution introduces a distinct set of concerns, moving beyond general patient education to encompass the occupational and environmental exposures that may arise during manufacturing, handling, and supply chain management. In this light, the historical emphasis on general health literacy now serves as a precursor to a more targeted inquiry: the potential for occupational exposure to Tysabri and the associated risk of Progressive Multifocal Leukoencephalopathy (PML). This pivot reframes the legacy of broad scientific communication as a necessary prelude to understanding the specific legal and temporal constraints, such as the statute of limitations, that govern claims arising from such exposure in a jurisdiction like Michigan.

Medical Evidence Linking Tysabri to PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease in adults. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Michigan who have developed PML after Tysabri treatment, understanding the medical evidence linking the drug to this harm, as well as the legal considerations regarding the statute of limitations for filing a claim, is essential. The prescribing information for Tysabri contains a boxed warning stating that the drug increases the risk of PML, an opportunistic viral infection of the brain that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML is caused by the JC virus and typically occurs only in patients who are immunocompromised. The label identifies three specific risk factors for developing PML in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing treatment, weighing expected benefit against the risk of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The clinical presentation of PML can include progressive neurological deficits such as weakness, visual changes, cognitive decline, and coordination problems. Diagnosis typically involves brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid. The label mandates that healthcare professionals monitor patients for any new sign or symptom suggestive of PML and withhold Tysabri immediately at the first such indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the risk of PML, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program, which requires regular evaluations and reporting of PML cases (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Mechanistic Pathways and Adequacy of Warnings

The mechanistic link between Tysabri and PML involves the drug's action as an alpha-4 integrin antagonist. By blocking the adhesion molecule VLA-4, Tysabri prevents immune cells from crossing the blood-brain barrier, reducing inflammation in the central nervous system. However, this immunosuppressive effect also impairs immune surveillance against the JC virus, which is normally controlled by the immune system. In the absence of adequate immune monitoring, the JC virus can reactivate and cause lytic infection of oligodendrocytes, leading to demyelination and the clinical syndrome of PML. The risk is highest in patients with anti-JCV antibodies, indicating prior exposure to the virus, and increases with cumulative treatment duration. The boxed warning on Tysabri's label explicitly states that the drug increases the risk of PML and describes the known risk factors. However, questions may arise about whether these warnings were adequate to inform patients and prescribers of the magnitude of risk, especially in the context of evolving understanding of risk stratification. The label requires monitoring and immediate withholding of Tysabri at the first sign of PML, but the insidious onset of symptoms can delay diagnosis. For patients who developed PML despite adherence to monitoring protocols, the adequacy of the warnings may be a central issue in legal claims.

Settlement-Related Considerations and Statute of Limitations in Michigan

For patients in Michigan who have been harmed by Tysabri-associated PML, settlement considerations include the severity of the injury, the timeline between exposure and documented harm, and the legal framework for product liability claims. The statute of limitations for filing a lawsuit in Michigan is generally three years from the date of injury or from when the injury was discovered, or should have been discovered, through reasonable diligence. Given that PML can develop months to years after starting Tysabri, the date of diagnosis is often the trigger for the limitations period. Patients should consult with an attorney experienced in pharmaceutical litigation to determine the applicable deadline for their specific case. The risk of PML increases with longer treatment duration, particularly beyond two years. The label notes that patients who are anti-JCV antibody positive have a higher risk, and prior use of immunosuppressants further elevates that risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The TOUCH program requires evaluations at three months, six months, and every six months thereafter, as well as for at least six months after discontinuing Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This structured monitoring is intended to detect PML early, but the disease can progress rapidly once symptoms appear. The interval between the first infusion and the onset of PML can range from months to several years, and the harm is often severe and irreversible.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri PML claims in Michigan?

In Michigan, the statute of limitations for product liability claims, including those related to Tysabri and PML, is generally three years from the date of injury or from when the injury was discovered, or should have been discovered, through reasonable diligence. Because PML can develop months to years after starting Tysabri, the date of diagnosis often triggers the limitations period. It is crucial to consult with an attorney promptly to preserve your right to seek compensation.

What medical evidence links Tysabri to PML?

The prescribing information for Tysabri includes a boxed warning that the drug increases the risk of PML, a severe brain infection caused by the JC virus (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Risk factors include the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. The label requires monitoring for symptoms and immediate withholding of Tysabri if PML is suspected.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Tysabri Prescribing Information (DailyMed)

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.